Kanamori, Toru
Kamei, Koichi
Sato, Mai
Nishi, Kentaro
Okutsu, Mika
Ishiwa, Sho
Ogura, Masao
Sako, Mayumi
Ishikura, Kenji
Ito, Shuichi http://orcid.org/0000-0002-5242-8987
Article History
Received: 22 June 2022
Accepted: 23 March 2023
First Online: 24 April 2023
Declarations
:
: Kamei has received research funding from the Terumo Foundation for Life Sciences and Arts, Public Foundation of Vaccination Research Center, and Taiju Life Social Welfare Foundation; donations from Chugai Pharmaceutical Co. Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co., Teijin Pharma Ltd. Shionogi Co. Ltd., and Otsuka Pharmaceutical Co. Ltd.; and lecture fees from Tanabe Mitsubishi Pharma, Baxter Ltd. and Zenyaku Kogyo Co. Ltd. Ishikura received grants from Asahi Kasei Pharma, Chugai Pharmaceutical Co., Ltd., Novartis Pharma, and Zenyaku Kogyo Co. Ltd. and lecture fees from Asahi Kasei Pharma, Chugai Pharmaceutical Co., Ltd., Zenyaku Kogyo Co., Ltd., and Novartis Pharma K.K. Ito received grants from Teijin Pharma Ltd, Astellas Pharma Inc., Pfizer Co. Ltd., and Tanabe Mitsubishi Pharma and lecture fees from Teijin Pharma Ltd and Sanofi Genzyme Co. Ltd.
: This study conformed to the principles of the Declaration of Helsinki and the ethical guidelines issued by the Ministry of Health, Labor, and Welfare in Japan. It was approved by the ethics committee of the NCCHD (approval number: 2403). Informed consent regarding participation was waived in accordance with the guidelines.
: Informed consent regarding publication was waived in accordance with the guidelines.